BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29599315)

  • 1. Melatonin Promotes Apoptosis of Oxaliplatin-resistant Colorectal Cancer Cells Through Inhibition of Cellular Prion Protein.
    Lee JH; Yoon YM; Han YS; Yun CW; Lee SH
    Anticancer Res; 2018 Apr; 38(4):1993-2000. PubMed ID: 29599315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melatonin Promotes Apoptosis of Colorectal Cancer Cells
    Yun CW; Kim S; Lee JH; Lee SH
    Anticancer Res; 2018 Jul; 38(7):3951-3960. PubMed ID: 29970517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of betulinic acid on anticancer drug-resistant colon cancer cells.
    Jung GR; Kim KJ; Choi CH; Lee TB; Han SI; Han HK; Lim SC
    Basic Clin Pharmacol Toxicol; 2007 Oct; 101(4):277-85. PubMed ID: 17845510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-myc downstream-regulated gene 1 promotes oxaliplatin-triggered apoptosis in colorectal cancer cells via enhancing the ubiquitination of Bcl-2.
    Yang X; Zhu F; Yu C; Lu J; Zhang L; Lv Y; Sun J; Zheng M
    Oncotarget; 2017 Jul; 8(29):47709-47724. PubMed ID: 28537875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of cytotoxicity, apoptosis and DNA damages in Colo320 colorectal cancer cells selected for oxaliplatin resistance.
    Virag P; Brie I; Fischer-Fodor E; Perde-Schrepler M; Tatomir C; Balacescu O; Irimie A; Postescu ID
    Cell Biochem Funct; 2011 Jul; 29(5):351-5. PubMed ID: 21491469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis.
    Hsu HH; Chen MC; Baskaran R; Lin YM; Day CH; Lin YJ; Tu CC; Vijaya Padma V; Kuo WW; Huang CY
    J Cell Physiol; 2018 Jul; 233(7):5458-5467. PubMed ID: 29247488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ursolic acid enhances the therapeutic effects of oxaliplatin in colorectal cancer by inhibition of drug resistance.
    Zhang Y; Huang L; Shi H; Chen H; Tao J; Shen R; Wang T
    Cancer Sci; 2018 Jan; 109(1):94-102. PubMed ID: 29034540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab.
    Prewett M; Deevi DS; Bassi R; Fan F; Ellis LM; Hicklin DJ; Tonra JR
    Clin Cancer Res; 2007 Dec; 13(24):7432-40. PubMed ID: 18094427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential therapeutic effect of melatonin in oxaliplatin combination therapy against chemoresistant colorectal cancer cells.
    Dehghanzad M; Mohammadi M; Nejati M; Pouremamali F; Maroufi NF; Akbarzadeh M; Samadi N; Nouri M
    Mol Biol Rep; 2024 Feb; 51(1):348. PubMed ID: 38401018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genipin Enhances the Therapeutic Effects of Oxaliplatin by Upregulating BIM in Colorectal Cancer.
    Kim BR; Jeong YA; Jo MJ; Park SH; Na YJ; Kim JL; Jeong S; Yun HK; Kang S; Lee DH; Oh SC
    Mol Cancer Ther; 2019 Apr; 18(4):751-761. PubMed ID: 30787174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (
    Combès E; Andrade AF; Tosi D; Michaud HA; Coquel F; Garambois V; Desigaud D; Jarlier M; Coquelle A; Pasero P; Bonnefoy N; Moreaux J; Martineau P; Del Rio M; Beijersbergen RL; Vezzio-Vie N; Gongora C
    Cancer Res; 2019 Jun; 79(11):2933-2946. PubMed ID: 30987998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ursolic acid synergistically enhances the therapeutic effects of oxaliplatin in colorectal cancer.
    Shan J; Xuan Y; Zhang Q; Zhu C; Liu Z; Zhang S
    Protein Cell; 2016 Aug; 7(8):571-85. PubMed ID: 27472952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of B7-H3 reverses oxaliplatin resistance in human colorectal cancer cells.
    Zhang P; Chen Z; Ning K; Jin J; Han X
    Biochem Biophys Res Commun; 2017 Aug; 490(3):1132-1138. PubMed ID: 28676400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Study of Autophagy in Oxaliplatin-Sensitive and Resistant SNU-C5 Colon Cancer Cells.
    Boo SJ; Piao MJ; Kang KA; Zhen AX; Fernando PDSM; Herath HMUL; Lee SJ; Song SE; Hyun JW
    Biomol Ther (Seoul); 2022 Sep; 30(5):447-454. PubMed ID: 35611548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superoxide-hydrogen peroxide imbalance interferes with colorectal cancer cells viability, proliferation and oxaliplatin response.
    Azzolin VF; Cadoná FC; Machado AK; Berto MD; Barbisan F; Dornelles EB; Glanzner WG; Gonçalves PB; Bica CG; da Cruz IB
    Toxicol In Vitro; 2016 Apr; 32():8-15. PubMed ID: 26674755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neural precursor cell expressed, developmentally downregulated 8‑activating enzyme inhibitor MLN4924 sensitizes colorectal cancer cells to oxaliplatin by inducing DNA damage, G2 cell cycle arrest and apoptosis.
    Zheng W; Luo Z; Zhang J; Min P; Li W; Xu D; Zhang Z; Xiong P; Liang H; Liu J
    Mol Med Rep; 2017 May; 15(5):2795-2801. PubMed ID: 28447739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
    Nukatsuka M; Nakagawa F; Takechi T
    Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Girdin enhances chemosensitivity of colorectal cancer cells to oxaliplatin.
    Zhang YJ; Li AJ; Han Y; Yin L; Lin MB
    World J Gastroenterol; 2014 Jul; 20(25):8229-36. PubMed ID: 25009397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The synergistic effects of oxaliplatin and piperlongumine on colorectal cancer are mediated by oxidative stress.
    Chen W; Lian W; Yuan Y; Li M
    Cell Death Dis; 2019 Aug; 10(8):600. PubMed ID: 31395855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer.
    Kemeny N; Jarnagin W; Paty P; Gönen M; Schwartz L; Morse M; Leonard G; D'Angelica M; DeMatteo R; Blumgart L; Fong Y
    J Clin Oncol; 2005 Aug; 23(22):4888-96. PubMed ID: 16009951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.